201 HASKINS WAY, SOUTH SAN FRANCISCO, CA
Reports Business Highlights and Financial Results for the First Quarter 2026
Annual Report to Security Holders
Reports Q4 and Full Year 2025 Business and Financial Results
Smital Shah Appointed Chief Financial and Business Officer
Other Events
Bylaw Amendments Approved by Lyell Immunopharma Board on December 3, 2025
Reports Business Highlights and Financial Results for the Third Quarter 2025
Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer
FY 2025
Q3
Q2
Q1
FY 2024
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Submission Upload
Correspondence